JNJ Maintains Rating by Morgan Stanley -- Price Target Lowered t
Morgan Stanley maintained its 'Overweight' rating for Johnson & Johnson (JNJ) but lowered its price target from $294.00 to $292.00. GuruFocus values JNJ at $194.40, suggesting a 31.7% overvaluation. The company has a GF Score™ of 83/100, with strong profitability and growth but weaker momentum. Insiders have sold $67.8M in shares over the last three months.
How this was made
The 30-second read
Why it matters
The slight target reduction may lead to short‑term price pressure, but the continued Overweight stance supports a neutral‑to‑positive longer‑term view.
Market read
Analyst rating updates with price‑target changes are modest catalysts for large‑cap stocks; traders may watch for short‑term moves.
What to watch
Insider selling of $67.8 M may indicate internal concerns not fully reflected in the modest target adjustment.
Background
Morgan Stanley analyst Terence Flynn updated Johnson & Johnson's rating on Oct 15, 2026, maintaining Overweight while trimming the price target from $294 to $292.
Ticker impact
Morgan Stanley kept its Overweight rating on Johnson & Johnson but lowered the price target to $292, indicating a modest bearish signal.
likely modest pressure as the market prices in the lower target
The downgrade of the price target, though small, signals reduced upside and may prompt short‑term selling.
Market effects
Healthcare sector may see slight caution as a major blue‑chip health‑care stock receives a lower target.
U.S. market sentiment could be mildly affected, especially among defensive stocks.
Limited; primarily relevant to investors tracking large‑cap U.S. health‑care equities.
Counterpoint
The price target cut is minimal; the Overweight rating remains, suggesting the stock could still outperform peers.
Key entities
- companyJohnson & Johnson
US‑listed health‑care conglomerate (ticker JNJ).
- financial_institutionMorgan Stanley
Equity research firm providing the rating update.
